Suxia Lin

Suxia Lin


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Theranostics
Verified
Journal Article
Open access
YZYing Zhang
Ying Zhang
ZLZhaoyong Liu
Zhaoyong Liu
XYXia Yang
Xia Yang
WLWeiqing Lu
Weiqing Lu
YCYelong Chen
Yelong Chen
JYJingping Yun
Jingping Yun
Background: Collagen type VI alpha 1 (COL6A1) has been found to be dysregulated in several human malignancies. However, the role of COL6A1 in osteosarcoma (OS) progression remains largely unclear. Here, we aimed to explore the clinical significance and biological involvement of COL6A1 in the OS cell migration and invasion.

11 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JZJing Zeng
Jing Zeng
XZXin-Ke Zhang
Xin-Ke Zhang
HCHua-Dong Chen
Hua-Dong Chen
ZZZhi-Hai Zhong
Zhi-Hai Zhong
QWQiu-Liang Wu
Qiu-Liang Wu
SLSuxia Lin
Suxia Lin
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas

9 March 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
MLMin Luo
Min Luo
YXYuhui Xia
Yuhui Xia
FWFang Wang
Fang Wang
HZHong Zhang
Hong Zhang
DSDanting Su
Danting Su
Liwu FuLiwu Fu
Liwu Fu
ERK pathway regulated the programmed death ligand-1 (PD-L1) expression which was linked to the response of programmed death-1 (PD-1)/PD-L1 blockade therapy. So it is deducible that ERK inhibitor could enhance the efficacy of PD-1 inhibitor in cancer immunotherapy. In this study, PD0325901, an oral potent ERK inhibitor, strongly enhanced the efficacy of PD-1 antibody in vitro and in vivo models in non-small cell lung carcinoma (NSCLC) cells. Mechanistically, PD0325901 or shRNA-ERK1/2 significantly downregulated the PD-L1 expression in NSCLC cells and increased the CD3+ T cells infiltration and functions in tumor tissue. There was a positive correlation between the p-ERK1/2 expression and PD-L1 expression in patients with NSCLC. And the patients with low p-ERK1/2 expression were observed a high response rate of PD-1/PD-L1 blockage therapy. Our results demonstrate that PD0325901, an ERK inhibitor, can enhance the efficacy of PD-1 blockage against NSCLC in vitro and in vivo models. And the combination of ERK inhibitor such as PD0325901 and PD-1/PD-L1 blockage is a promising regimen and encouraged to be further confirmed in the treatment of patients with NSCLC.

2 December 2011 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
NLNing Lv
Ning Lv
XXXiaoming Xie
Xiaoming Xie
QGQidong Ge
Qidong Ge
SLSuxia Lin
Suxia Lin
XWXi Wang
Xi Wang
WWWeidong Wei
Weidong Wei
Background: The epidermal growth factor receptor (EGFR) is an available target of effective anti-EGFR therapy for human breast cancer. The aim of this study was to assess the presence of EGFR gene amplification and mutations in breast cancer and to analyze the association between the statuses of these two gene alterations.Materials and methods: EGFR gene amplification and mutations were investigated in formalin-fixed, paraffin-embedded tissues from 139 Chinese female patients with breast cancer by means of fluorescence in-situ hybridization (FISH) and fluorescently labeled real-time quantitative polymerase chain reaction (RT-PCR), respectively.Results: EGFR gene amplification was observed in 46/139 (33.1%) of cases by FISH. Based on RT-PCR, 2/139 (1.4%) samples had EGFR gene mutations. Overall, only 1 (0.7%) of the cases was identified with both whole gene amplification and mutation, and 92 (66.2%) of cases were negative for both. High gene copy numbers of EGFR had significant correlation with the occurrence of EGFR protein expressions (P = 0.002).Conclusion: In this study, EGFR mutations were presented in only two samples, indicating that EGFR mutations should not be employed in future trials with anti-EGFR therapies for breast cancer. However, EGFR whole gene amplification is frequently observed in patients with breast cancer. It will be of significant interest to investigate whether EGFR gene copy number is a suitable screening test for EGFR-targeted therapy for breast cancer.Virtual Slides: The virtual slides for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/2521111805741248

15 September 2021 in iScience
Verified
Journal Article
Open access
RGRui Gao
Rui Gao
BHBin He
Bin He
QHQitao Huang
Qitao Huang
ZWZifeng Wang
Zifeng Wang
MYMin Yan
Min Yan
QLQuentin Liu
Quentin Liu
Immune transcripts are essential for depicting onco-immunologic interactions. However, whether cancer cells mimic immune transcripts to reprogram onco-immunologic interaction remains unclear. Here, single-cell transcriptomic analyses of 7,737 normal and 37,476 cancer cells reveal increased immune transcripts in cancer cells. Cells gradually acquire immune transcripts in malignant transformation. Notably, cancer cell-derived immune transcripts contribute to distinct prognoses of immune gene signatures. Optimized immune response signature (oIRS), obtained by excluding cancer-related immune genes from immune gene signatures, and offers a more reliable prognostic value. oIRS reveals that antigen presentation, NK cell killing and T cell signaling are associated with favorable prognosis. Patients with higher oIRS expression are associated with favorable responses to immunotherapy. Indeed, CD83+ cell infiltration, which indicates antigen presentation activity, predicts favorable prognosis in breast cancer. These findings unveil that immune mimicry is a distinct cancer hallmark, providing an example of cancer cell plasticity and a refined view of tumor microenvironment.

20 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LHLina Hu
Lina Hu
XZXuanye Zhang
Xuanye Zhang
HLHuifeng Li
Huifeng Li
SLSuxia Lin
Suxia Lin
SZshengbing zang
shengbing zang
Angioimmunoblastic T-cell lymphoma (AITL), a type of malignant lymphoma with unique genomic aberrations, significant clinicopathological features, and poor prognosis, is characterized by immune system dysregulation. Recent sequencing studies have identified recurrent mutations and interactions in tet methylcytosine dioxygenase 2 (TET2), ras homology family member A (RHOA), DNA methyltransferase 3 alpha (DNMT3A), and mitochondrial isocitrate dehydrogenase II (IDH2). Notably, since B-cell lymphomas are frequently observed along with AITL, this review first summarizes its controversial mechanisms based on traditional and recent views. Epigenetic regulation represented by TET2 plays an increasingly important role in understanding the multi-step and multi-lineage tumorigenesis of AITL, providing new research directions and treatment strategies for patients with AITL. Here, we review the latest advances in our understanding of AITL and highlight relevant issues that have yet to be addressed in clinical practice.